Neogenomics opened higher at $17.95, compared with its previous close of $17.93. In the last trading session, the stock traded between $17.09 and $18.15. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Neogenomics is now worth
$ 37.51
resulting in a loss of
$ 62.49 (62.49%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
$-0.68 (-3.76%)
Day High
$18.15
Day Low
$17.09
Day Open
$17.95
Prev Close
$17.93
Volume
6,83,152
1W Return
5.27%
1M Return
-7.93%
3M Return
13.14%
6M Return
92.58%
1Y Return
67.85%
Market Cap ($ Mn)
2,233
PE Ratio
-
PB Ratio
2.94
PEG Ratio
-
ROE
-12.50%
ROCE
-8.89%
EPS (TTM)
$-0.06
1 Week
5.27%
1 Month
-7.93%
3 Months
13.14%
6 Months
92.58%
9 Months
39.15%
NeoGenomics expands Indica Labs partnership to scale AI pathology
NeoGenomics expanded its partnership with Indica Labs to scale digital pathology infrastructure. The deal utilizes the HALO AP® platform to enable cloud-based, vendor-neutral image management. NeoGenomics aims to reduce integration costs and capital investment through flexible AI tool adoption. The infrastructure supports future AI co-development and clinical trial collaborations.
15 days agoNeoGenomics names Warren Stone CEO; Q3 revenue hits $209 million
Warren Stone appointed CEO effective January 4, 2027. Tony Zook transitions to Executive Chair role. Preliminary Q3 revenue reaches $209 million. NGS revenue grows 28% year-over-year. Full-year revenue guidance expected to increase.
24 days agoNeoGenomics Q3FY26 Results: Revenue ~$209M, Guidance Reiterated
NeoGenomics reported Q3 revenue of approximately $209 million. Full-year FY2026 revenue and adjusted EBITDA guidance remain unchanged. Company plans to raise the revenue guidance midpoint on the earnings call.
24 days agoNeoGenomics to present at Morgan Stanley global healthcare conference
NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, held Sept. 14-16, 2026, in New York, NY. Management's fireside chat is scheduled for Tuesday, Sept. 15, at 7:45 am ET. A live audio webcast will be available during the session, with an archived replay posted to ir.neogenomics.com. NeoGenomics operates CAP-accredited and CLIA-certified laboratories across the US and a CAP-accredited laboratory in Cambridge, United Kingdom.
1mo agoNeoGenomics RaDaR ST assay wins expanded CMS coverage for immunotherapy
NeoGenomics RaDaR ST assay gains expanded CMS MolDX coverage for immunotherapy monitoring in late-stage solid tumors. This is the third Medicare-covered indication, adding to HPV-negative head and neck and HR+/HER2-negative breast cancer uses. Two additional RaDaR ST submissions are pending with MolDX for further coverage expansion. Immunotherapy accounts for 55% of lung cancer and 70% of melanoma treated cases, highlighting significant addressable market.
2mo agoNeoGenomics Q2 Results: Adj. EPS beats estimate by 66.67%
NeoGenomics delivered a strong second-quarter performance, with adjusted EPS of $0.05 beating the $0.03 estimate by 66.67%. Sales of $202.000 million also exceeded the $196.997 million estimate by 2.54%, reflecting an 11.40% year-over-year increase from $181.330 million.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 5 years ago in Neogenomics is now worth
$ 37.51
resulting in a loss of
$ 62.49 (62.49%)
Note: Past profits do not guarantee future returns.
